PATH-21. ANGIOTENSINOGEN GENE SILENCING PREDICTS BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS

BACKGROUND: Bevacizumab in combination with chemotherapy has shown activity in recurrent glioblastoma patients, with responding patients having improved survival as well as quality of life. Recently, we found that low gene expression of angiotensinogen (AGT) was predictive for bevacizumab response i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Urup, Thomas, Gillberg, Linn, Michaelsen, Signe, Christensen, Ib, Broholm, Helle, Lassen, Ulrik, Groenbaek, Kirsten, Poulsen, Hans
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2018
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216569/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.677
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky